Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China
2020 · Infection · 277 citations
https://doi.org/10.1007/s15010-020-01432-5
H
Huijuan Wu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
179
Papers
5.1K
Citations
33
h-index
82
i10-index
Huijuan Wu is an academic researcher from Guangzhou University of Chinese Medicine. The author has contributed to research in topics: Renal Diseases and Glomerulopathies & Chronic Kidney Disease and Diabetes & Hippo pathway signaling and YAP/TAZ. The author has an h-index of 33, co-authored 153 publications.
ORCID: 0000-0003-4681-4440Papers by this author
worksBone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1
2020 · Cell Death and Disease · 154 citations
https://doi.org/10.1038/s41419-020-02962-4
Hippo-YAP/MCP-1 mediated tubular maladaptive repair promote inflammation in renal failed recovery after ischemic AKI
2021 · Cell Death and Disease · 89 citations
https://doi.org/10.1038/s41419-021-04041-8
NLRP3 associated with chronic kidney disease progression after ischemia/reperfusion-induced acute kidney injury
2021 · Cell Death Discovery · 44 citations
https://doi.org/10.1038/s41420-021-00719-2
Nuclear exclusion of YAP exacerbates podocyte apoptosis and disease progression in Adriamycin-induced focal segmental glomerulosclerosis
2020 · Laboratory Investigation · 34 citations
https://doi.org/10.1038/s41374-020-00503-3
Uremic Toxin Receptor AhR Facilitates Renal Senescence and Fibrosis via Suppressing Mitochondrial Biogenesis
2024 · Advanced Science · 30 citations
https://doi.org/10.1002/advs.202402066
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat